News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 13, 2020

How Children and Adolescents Are Responding to the Pandemic

Author(s)Leela Magavi, MD

A child/adolescent and adult psychiatrist answers three key questions regarding youth and COVID-19.

A child/adolescent and adult psychiatrist will answers three questions regarding youth and COVID-19. Leela Magavi, MD, is Regional Director of Community Psychiatry, in Newport Beach, CA.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

lithium semaglutide GLP1

Semaglutide Potentially Protective Against Nephrotoxicity Caused by Lithium

ByJessica Walters

December 10th 2025

Manish Zinzuvadia, MD

Challenges in Bipolar Disorder: Discussion With Manish Zinzuvadia, MD

ByManish Zinzuvadia, MD

December 2nd 2025

adolescent psychiatry lifestyle medicine obesity

Youth Lifestyle Psychiatry: Addressing Obesity in the Psychiatric Setting

ByTiffani L. Bell Washington, MD, MPH, FAPA,Jessica Walters

November 26th 2025

bipolar disorder

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

ByAndrew Nguyen, MD, MSc,Ayal Schaffer, MD, FRCPC

November 26th 2025

ADHD NDA NDSRI child adolescent

New Drug Application Submitted for Centanafidine for Treatment of ADHD

ByJessica Walters

November 25th 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia

Transcranial Magnetic Stimulation in Sports Performance: Promise, Physiology, and Precaution

FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia

Semaglutide Potentially Protective Against Nephrotoxicity Caused by Lithium

Evenamide for Treatment-Resistant Schizophrenia: Initiation of ENIGMA-TRS 2 Phase 3 Clinical Study

© 2025 MJH Life Sciences^®

All rights reserved.